AI Article Synopsis
Article Abstract
Drug delivery in the brain is challenging due to the existence of the blood brain barrier, which prevents most drugs from entering the target site in the brain. Compared to systematic drug administration, localized and site-specific drug delivery in a minimally invasive manner is effective for the treatment of brain disease. However, its implementation relies on advanced technologies and miniaturized implants/devices for controllable drug delivery. Recent research endeavors have provided a broad range of creative neural implants and platforms for this purpose. In this review, we provide an overview of recent advances in miniaturized neural implants for precise, controllable and minimally invasive drug delivery in the brain. This review will focus on neural implants with proven functionalities by discussing the technologies and materials used to fabricate these miniaturized multi-functional drug delivery implants with either externally connected pumps or integrated microfluidic pumps. The vibrancy of engineering technologies and emerging materials associated with these implants and their significance to targeted and minimally invasive drug delivery for brain disease treatment will motivate continued advance and growth of this area of research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/d3tb00728f | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tailoring Design of Microneedles for Drug Delivery and Biosensing.
Mol Pharm
January 2025
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Microneedles (MNs) are emerging as versatile tools for both therapeutic drug delivery and diagnostic monitoring. Unlike hypodermic needles, MNs achieve these applications with minimal or no pain and customizable designs, making them suitable for personalized medicine. Understanding the key design parameters and the challenges during contact with biofluids is crucial to optimizing their use across applications.
View Article and Find Full Text PDFInterventions to Maintain HIV/AIDS, Tuberculosis, and Malaria Service Delivery During Public Health Emergencies in Low- and Middle-Income Countries: Protocol for a Systematic Review.
JMIR Res Protoc
January 2025
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Background: Although existing disease preparedness and response frameworks provide guidance about strengthening emergency response capacity, little attention is paid to health service continuity during emergency responses. During the 2014 Ebola outbreak, there were 11,325 reported deaths due to the Ebola virus and yet disruption in access to care caused more than 10,000 additional deaths due to measles, HIV/AIDS, tuberculosis, and malaria. Low- and middle-income countries account for the largest disease burden due to HIV, tuberculosis, and malaria and yet previous responses to health emergencies showed that HIV, tuberculosis, and malaria service delivery can be significantly disrupted.
View Article and Find Full Text PDFEvaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs.
J Med Chem
January 2025
Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
PROTACs usually occupy physicochemical space outside the one defined by classical drug-like molecules, which often presents considerable challenges in their optimization and development for oral administration. We have previously reported phenyl glutarimide (PG)-based BET PROTAC SJ995973, with improved overall degradation and antiproliferative activities compared to its direct thalidomide-based analogue dBET1, but similarly poor pharmacokinetic profile. To further demonstrate the PG utility, we describe here optimization efforts that led to the discovery of an orally bioavailable BET-PROTAC SJ44236 (), and results of a comprehensive comparative study with analogues containing alternative CRBN-directing warheads.
View Article and Find Full Text PDFMacrophage-specific in vivo RNA editing promotes phagocytosis and antitumor immunity in mice.
Sci Transl Med
January 2025
College of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China.
Macrophages play a central role in antitumor immunity, making them an attractive target for gene therapy strategies. However, macrophages are difficult to transfect because of nucleic acid sensors that can trigger the degradation of foreign plasmid DNA. Here, we developed a macrophage-specific editing (MAGE) system by which compact plasmid DNA encoding a CasRx editor can be delivered to macrophages by a poly(β-amino ester) (PBAE) carrier to bypass the DNA sensor and enable RNA editing in vitro and in vivo.
View Article and Find Full Text PDFImpulse control disorders in Parkinson's disease: What's new?
J Neurol
January 2025
Parkinson's Disease Research Clinic, Macquarie University, 75 Talavera Road, Sydney, NSW, 2109, Australia.
Impulse Control Disorders (ICDs) are increasingly recognized as a significant non-motor complication in Parkinson's disease (PD), impacting patients and their caregivers. ICDs in PD are primarily associated with dopaminergic treatments, particularly dopamine agonists, though not all patients develop these disorders, indicating a role for genetic and other clinical factors. Studies over the past few years suggest that the mesocorticolimbic reward system, a core neural substrate for impulsivity, is a key contributor to ICDs in PD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!